

Mark A Socinski¹; Leigh M Boehmer²

¹AdventHealth Cancer Institute, Orlando, FL; ²Association of Community Cancer Centers, Rockville, MD

INTRODUCTION


- The rapidly evolving staging system, diagnostic procedures, and treatment options have added complexity to existing treatment algorithms for non-small cell lung cancer (NSCLC).¹ Furthermore, fragmentation of the U.S. healthcare system impedes consistent access to equitable care
- Although multiple aspects of NSCLC management are addressed by existing guidelines,^{2,3} several critical features, including patient education on all aspects of NSCLC (e.g., diagnosis, staging, and treatment), and access to a multidisciplinary team (MDT) care navigator for information on financial aspects of the treatment remain unaddressed
- Consequently, guidance spanning the complete care pathway is lacking

OBJECTIVE

- To provide a quality benchmark for cancer programs by defining ideal care in different aspects of NSCLC management, with emphasis on MDT management

METHODS

Figure 1: Stepwise development of recommendations for the multidisciplinary team and selected clinical criteria for ideal NSCLC care



ACCC, Association of Community Cancer Centers; ASCO, American Society of Clinical Oncology; CoC, Commission on Cancer; ESMO, European Society for Medical Oncology; NCCN®, National Comprehensive Cancer Network®; NSCLC, non-small cell lung cancer; QOPI®, Quality Oncology Practice Initiative®.

CONCLUSIONS

- The full set of recommendations defines ideal NSCLC care, serves as a valuable guide for quality improvement initiatives, and could encourage multidisciplinary community cancer care programs to not only improve their care but also develop metrics to measure care improvement
- The quality measures described herein can be used to supplement existing guidelines in guiding clinical practice
- Importantly, recommendations on quality improvements are applicable across diverse patient groups to provide equal access to quality NSCLC care

REFERENCES

- Melosky B. Rapidly changing treatment algorithms for metastatic nonsquamous non-small-cell lung cancer. *Curr Oncol*. 2018;25(Suppl 1):S68-S76.
- National Comprehensive Cancer Network® Clinical Practice Guidelines in Oncology. Non-Small Cell Lung Cancer. Version 2.2020. Available from: <https://www.nccn.org>; last accessed: August 19, 2020.
- Planchard D, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2018;29(Suppl 4):iv192-iv237.

FUNDING

Funding for this initiative, including the survey, was provided by AstraZeneca.

DISCLOSURES

Authors report no conflicts of interest with respect to the development of this poster.

ACKNOWLEDGMENTS


- The multiphase initiative, "Fostering Excellence in Care and Outcomes in Patients with Stage III and IV NSCLC," involved the following partner organizations: the American College of Chest Physicians (CHEST), the International Association for the Study of Lung Cancer (IASLC), and the LUNGevity Foundation
- The authors are grateful for the contributions of the steering committee, patient advocacy partners, and survey methodology experts:
 - Steering committee: David Spigel, Jennifer Aversano, David Feller-Kopman, Percy Lee, Nicholas Robert, Ravi Salgia, S Michelle Shiller, Mark Socinski, Alex Spira, Brendon Stiles, Karen Van De Steeg, and Howard (Jack) West
 - Patient advocacy partners: Andrea Ferris (LUNGevity Foundation) and Nikki Martin (LUNGevity Foundation)
 - Survey methodology experts: Matthew Smeltzer (University of Memphis) and Joe Kim (Xaf Solutions)
- The authors thank all ACCC survey respondents at cancer programs nationwide for participating in the survey and providing valuable insights on NSCLC care delivery
- Data analysis services were provided by Elite Research, and medical writing support for the development of this poster was provided by Saurabh Gagangras and Juliane Moloney of Cactus Life Sciences (part of Cactus Communications), in accordance with Good Publication Practice guidelines (<https://www.ismpp.org/gpp3>). The authors retained full control over the content and approved the final version for submission

- The Association of Community Cancer Centers (ACCC), a nonprofit, collaborative, and diverse cancer care organization, convened an expert steering committee of multidisciplinary specialists and representatives from patient advocacy and professional associations to identify aspects of NSCLC care not addressed in nationally recognized quality measures, define metrics for ideal NSCLC care, and compile evidence-based recommendations via a systematic search of clinical and quality care guidelines and peer-reviewed journals (**Figure 1**)

RESULTS

- A total of 32 quality recommendations were organized within four key care areas of the patient journey: diagnosis and biomarker testing, staging and treatment planning, care coordination and patient education, and survivorship (**Supplementary video**)
- Key quality recommendations are listed in **Figure 2** and included:
 - Involvement of an MDT care navigator, patient participation in shared decision-making, and patient education on NSCLC management
 - Use of a broader range of molecular tests and multidisciplinary evaluation of suspicious findings, MDT coordination for efficient biopsy collection, repeat biopsy/plasma testing for insufficient tissue, incorporation of invasive staging procedures, optimal staging, use of biomarker testing to inform clinical decisions, implementation of standardized protocols for short- and long-term surveillance, and provision of survivorship care plans

Figure 2: Key quality recommendations for ideal NSCLC care



*All patients in the U.S. who meet current screening standards should be screened for NSCLC. MDT, multidisciplinary team; NSCLC, non-small cell lung cancer.

Supplementary video: Summary of 32 quality recommendations

Please access the video using the following link:
<https://www.accc-cancer.org/projects/nsclc-care-delivery/nsclc-presentation-detail/improving-care-for-patients-with-nsclc-learnings-for-multidisciplinary-teams-at-asco-qcs>